Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyoung Su | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Jang, Myoung Kuk | - |
dc.contributor.author | Park, Ji Won | - |
dc.contributor.author | Suh, Sang Jun | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Kim, Ji Hoon | - |
dc.contributor.author | Kim, Bo Hyun | - |
dc.contributor.author | Park, Sang Jong | - |
dc.contributor.author | Lee, Sae Hwan | - |
dc.contributor.author | Kim, Sang Gyune | - |
dc.contributor.author | Kim, Young Seok | - |
dc.contributor.author | Lee, Jung Il | - |
dc.contributor.author | Lee, Jin-Woo | - |
dc.contributor.author | Kim, In Hee | - |
dc.contributor.author | Kim, Tae Yeob | - |
dc.contributor.author | Kim, Jin-Wook | - |
dc.contributor.author | Jeong, Sook-Hyang | - |
dc.contributor.author | Jung, Young Kul | - |
dc.contributor.author | Park, Hana | - |
dc.contributor.author | Hwang, Seong Gyu | - |
dc.date.available | 2020-02-28T07:44:39Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2015-10-14 | - |
dc.identifier.issn | 1007-9327 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/10035 | - |
dc.description.abstract | AIM: To evaluate the long-term efficacy adefovir (ADV)-based combination therapies in entecavir (ETV)-resistant chronic hepatitis B (CHB) patients. METHODS: Fifty CHB patients with genotypic resistance to ETV at 13 medical centers in South Korea were included for the analysis. All the patients received rescue therapy with the combination of ADV plus ETV (ADV/ETV, n = 23) or ADV plus lamivudine (LMV) (ADV/LMV, n = 27) for more than 12 mo. Patients were monitored at least every 3-4 mo during ADV-based combination therapy by clinical examination as well as biochemical and virological assessments. Hepatitis B virus (HBV) DNA levels were measured by real-time PCR and logarithmically transformed for analysis. Cumulative rates of virologic response (VR; HBV DNA < 20 IU/mL) were calculated using the Kaplan-Meier method, and the difference was determined by a log-rank test. Multivariate logistic regression and Cox proportional hazards models were used to identify independent risk factors significantly associated with short-term and long-term VR, respectively. RESULTS: Baseline median HBV DNA levels were 5.53 (2.81-7.63) log10 IU/mL. The most commonly observed ETV genotypic mutation sites were rt184 and rt202. Patients were treated for a median of 27 (12-45) mo. Overall, cumulative VR rates at 6, 12, 24, and 36 mo were 26%, 36%, 45%, and 68%, respectively. Patients treated with the ADV/ETV combination showed higher cumulative VR rates (35%, 43%, 65%, and 76%, respectively) than those with the ADV/LAM combination (18%, 30%, 30%, and 62%, respectively; P = 0.048). In the multivariate analysis, low baseline HBV DNA levels (< 5.2 log10 IU/mL) and initial virologic response at 3 mo (IVR-3; HBV DNA < 3.3 log10 IU/mL after 3 mo) were independent predictive factors for VR. Patients with favorable predictors achieved cumulative VR rates up to 90% at 36 mo. During the same period, the cumulative incidence of virologic breakthrough was as low as 6% in patients with the both favorable predictors. CONCLUSION: If tenofovir is not available, ADV/ETV combination could be considered in ETV-resistant patients with low HBV DNA titers, and may be continued if IVR-3 is achieved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BAISHIDENG PUBLISHING GROUP INC | - |
dc.relation.isPartOf | WORLD JOURNAL OF GASTROENTEROLOGY | - |
dc.subject | TENOFOVIR COMBINATION | - |
dc.subject | VIROLOGICAL RESPONSE | - |
dc.subject | VIRUS RESISTANCE | - |
dc.subject | LAMIVUDINE | - |
dc.subject | EFFICACY | - |
dc.subject | INFECTION | - |
dc.subject | UPDATE | - |
dc.title | Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000363267200017 | - |
dc.identifier.doi | 10.3748/wjg.v21.i38.10874 | - |
dc.identifier.bibliographicCitation | WORLD JOURNAL OF GASTROENTEROLOGY, v.21, no.38, pp.10874 - 10882 | - |
dc.identifier.scopusid | 2-s2.0-84944104840 | - |
dc.citation.endPage | 10882 | - |
dc.citation.startPage | 10874 | - |
dc.citation.title | WORLD JOURNAL OF GASTROENTEROLOGY | - |
dc.citation.volume | 21 | - |
dc.citation.number | 38 | - |
dc.contributor.affiliatedAuthor | Jung, Young Kul | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Adefovir | - |
dc.subject.keywordAuthor | Chronic hepatitis B | - |
dc.subject.keywordAuthor | Entecavir | - |
dc.subject.keywordAuthor | Lamivudine | - |
dc.subject.keywordAuthor | Resistance | - |
dc.subject.keywordPlus | TENOFOVIR COMBINATION | - |
dc.subject.keywordPlus | VIROLOGICAL RESPONSE | - |
dc.subject.keywordPlus | VIRUS RESISTANCE | - |
dc.subject.keywordPlus | LAMIVUDINE | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordPlus | UPDATE | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.